[Effects of a specific thromboxane A2 synthetase inhibitor on lymphocyte and neutrophil functions in adult intractable asthmatics].
To clarify whether thromboxane A2 (TXA2) is involved in type III and IV allergy, or so called "cell-mediated allergy", we studied the effect of a specific TXA2 synthetase inhibitor, sodium ozagrel (OKY-046) on peripheral blood mononuclear cells and neutrophils in adult intractable asthmatics. The results revealed, firstly, that lymphocyte blastogenesis and interleukin-2 (IL-2) production from peripheral blood mononuclear cells stimulated by PHA and Candida antigen in intractable asthmatics was significantly suppressed dose-dependently by OKY-046. Secondly, there was a tendency that neutrophil chemotactic factor (NCF) and eosinophil chemotactic factor (ECF) from peripheral blood mononuclear cells stimulated by Candida antigen in intractable asthmatics were suppressed by OKY-046. Thirdly, leukotriene (LTC4) and superoxide (O2-) production from peripheral blood neutrophils in intractable asthmatics was significantly suppressed dose-dependently by OKY-046. That is, OKY-046 has a suppressive effect on type IV allergy caused by lymphocyte activation and on mediator release from neutrophils. These results suggest that TXA2 plays an important role in the development of bronchial asthma and OKY-046 might be a useful drug in the treatment of intractable asthmatics.
Kanehiro
A
A
Second Department of Medicine, Okayama University Medical School.
Takahashi
K
K
Soda
R
R
Takata
M
M
Takeda
K
K
Sugano
H
H
Yamagata
K
K
Katagi
Y
Y
Kimura
I
I
D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy / Q000276:immunology*; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008689:Methacrylates / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism; D013189:SRS-A / Q000096:biosynthesis; D013481:Superoxides / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007376:Interleukin-2; D016209:Interleukin-8; D008689:Methacrylates; D013189:SRS-A; D013481:Superoxides; D013930:Thromboxane-A Synthase; C034364:ozagrel